In early November 2025, Akeso announced a series of pipeline milestones, including the first patient dosing in a Phase I trial of its mRNA vaccine AK154, the presentation of promising Overall Survival...
Source LinkIn early November 2025, Akeso announced a series of pipeline milestones, including the first patient dosing in a Phase I trial of its mRNA vaccine AK154, the presentation of promising Overall Survival...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.